Annals of Oncology Advance Access originally published online on November 5, 2009
Annals of Oncology 2009 20(12):2019; doi:10.1093/annonc/mdp503
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
letters to the editor |
Reply to Bone morphogenetic proteins and zoledronic acid
| The first 10% of the full text of this article appears below. |
Besides the various hypotheses that we proposed in our initial paper to explain the antitumor activity of bisphosphonates in
1 Department of Endocrinology, Center for Rare Adrenal Diseases
2 Department of Oncology
3 Department of Hepatobiliary Surgery, Assistance Publique – Hôpitaux de Paris, Hôpital Cochin, Paris Descartes University, Faculty of Medecine, Paris, France
* (E-mail: xavier.bertagna@cch.aphp.fr)